News | October 11, 2024
Privi Speciality Chemicals gets USFDA certificate for camphor product
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Aims to achieve CDMO sales of US$ 400 million by 2028
We now rank 3rd in pharmaceutical production by volume and 14th by value
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
CSPC will receive an upfront payment of $100 million from AstraZeneca
Strategic focus on COCO-model with a nationwide reach of 501 stores
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Subscribe To Our Newsletter & Stay Updated
